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The appropriate method of reperfusion for patients 75
years with ST-elevation acute myocardial infarction (AMI)
is one of the great enigmas of acute care cardiology. The
population at risk is large, comprising roughly one-third of
AMI patients and more than one half of AMI mortality (1).
Yet there have been no randomized trials focusing specifi-
cally on these high-risk patients who have been notably
underrepresented in randomized trials. Meta-analyses of
large randomized trials of thrombolytic therapy (2,3) have
found diminished relative benefit from thrombolytic therapy
but persistent absolute benefit, with 1.0 to 3.4 lives saved per
100 patients treated. Two large observational studies (4,5)
suggest that for patients 75 years, thrombolytic therapy
involves no benefit and possible harm, despite the fact that
elderly thrombolytic patients actually are healthier than
those managed without reperfusion therapy. Given the
limitations of both randomized trials, whose protocol-
controlled therapy and ideal patients are sometimes quite
different from community practice, where patients tend to
be older, with a longer symptom-to-presentation interval,
greater comorbidity and more relative contraindications;
and of observational studies, which are inherently liable to
unmeasured selection bias, expert opinion has remained
conflicted.
See page 1723
The study by de Boer et al. (6) in this issue of the Journal
begins to shed some light on this subject. Beginning in
March 1996, for three years their Dutch hospital enrolled
87 patients 75 years who met standard criteria for throm-
bolytic therapy in a prospective, randomized trial comparing
direct angioplasty with intravenous streptokinase. As al-
ways, the success rate of primary angioplasty depends on the
reckoning method. The authors describe a success rate of
90% (37 patients, 41 attempted angioplasties); a less opti-
mistic intention-to-treat reckoning might also include some
or all of the following: one patient who died prior to
angiography; two patients referred for bypass surgery after
angiography; and two patients managed conservatively after
angiography. Thus, the actual angioplasty success rate was
between 80% (37 successful angioplasties among 46 patients
randomized) and 90%. Of angioplasty patients, 51% re-
ceived stents; glycoprotein IIb/IIIa inhibitors were not used.
The results are startling. The 30-day mortality was 7% in
the angioplasty arm compared to 20% in the thrombolytic
arm (p  0.04); one-year mortality was 11% versus 29%
(p  0.03); and a composite end point of death, recurrent
MI or stroke during 20 months of follow-up was 8% versus
17% (p  0.004). The cardiology literature is replete with
trials enrolling tens of thousands of patients to demonstrate
an absolute 30-day mortality benefit of barely 1% and a
relative benefit of 10% to 20%; this small trial showed an
absolute 30-day mortality benefit of 13% and a relative
benefit of 35%, which persisted unchanged for the 20-
month term of the study.
The robustness of any study’s findings depend on meth-
odologic nuances. The study by de Boer et al. (6) is fairly
rigorous; it enrolled nearly all eligible patients (albeit using
a verbal consent that might dismay an American institu-
tional review board), used telephone randomization and had
complete follow-up for survivors. Although novel to some
Americans, the choice of streptokinase as a thrombolytic
agent needs no apology; this agent, if anything, is preferable
to tissue plasminogen activator in the elderly, with a lower
risk of catastrophic intracerebral hemorrhage and death (7).
Allowing for unstable point estimates in this small study,
thrombolytic 30-day mortality is comparable to most other
reports, such as the 18% 30-day mortality for patients age 76
to 86 years in a large 1994 to 1995 observational study (4)
and 19% in a similar subgroup of the Global Utilization of
Streptokinase and t-PA for Occluded Arteries (GUSTO I)
study (7), although considerably higher than the 11% rate
for patients 80 years in GUSTO IIB (8). Angioplasty
mortality also is roughly consistent with reports from other
randomized trials (9,10).
The present study also has significant weaknesses. With a
planned sample of 266 patients, the study was stopped early
in April 1999, after enrollment of 87 patients, with a p value
of 0.01 for the primary end point, a 30-day composite
outcome of death, recurrent MI and stroke. The report does
not describe predefined stopping criteria, scheduled interim
analyses by an independent data safety and monitoring
panel or statistical adjustment of the alpha threshold for
multiple looks, all of which typically require a lower p value
for early stopping than for tests of significance after com-
plete enrollment. While the p value for the composite end
point during 20 months of follow-up was 0.004, the p value
for 30-day mortality (a less ambiguous end point) was 0.04
and some may find that the study was stopped too soon.
Like many studies of primary angioplasty, the present
study also inherently involves an uncontrolled co-
intervention in the percutaneous intervention arm, in that
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nearly all patients underwent angiography and 85% under-
went percutaneous or surgical revascularization, compared
to only 10% of patients treated with streptokinase. By
comparison, in observational U.S. data, 32.5% of patients
75 years underwent revascularization within 30 days (4).
The possibility that more aggressive use of predischarge
noninvasive testing, angiography and revascularization
would materially alter mortality among thrombolytic pa-
tients cannot be excluded.
Both of these concerns, together with the inherent
limitations and potential publication bias of single-center
studies, render the report by de Boer et al. (6) exploratory
rather than definitive, as the authors acknowledge. How-
ever, the study is consistent with subgroup analysis of three
small randomized trials of angioplasty versus thrombolytic
therapy (10), which suggested special benefit for angioplasty
in elderly patients with ST-elevation MI. This inference
was not supported by the rigorous analysis of Holmes et al.
(9), which found no evidence of age interaction in the
1,138-patient GUSTO IIb study, but this study’s methods
necessarily had limited power to detect nonlinear interac-
tions such as those potentially present among elderly pa-
tients.
Although nonrandomized, retrospective studies reporting
marked benefit for primary angioplasty in elderly patients
have been widely published, the grave limitations of such
observational comparisons are seldom acknowledged. Ret-
rospective databases cannot identify patients who died while
awaiting primary angioplasty or those in whom angioplasty
was not attempted after coronary angiography, a group that
comprises 10% to 19% of the primary angioplasty groups in
randomized trials (11% in the study by de Boer et al. [6])
and has a mortality as high as 14.1% (11), several times the
mortality of patients who actually undergo primary angio-
plasty. These limitations render observational studies essen-
tially useless for fair comparison of angioplasty and throm-
bolytic therapy.
Even disregarding observational reports, in light of the
study of de Boer et al. (6), the preponderance of the
randomized trial evidence suggests a special benefit to
primary angioplasty in patients 75 years—provided that
patients are treated at a center whose experience, volume
and door-to-balloon time approach those in the trial of de
Boer et al. (6). These are large caveats. While small
randomized trials have achieved median door-to-balloon
intervals of about 60 min, a large community-based trial (8)
had an interval of 1.9 h and observational studies have
consistently found even longer times in community practice.
Berger et al. (12) reported a mean door-to-treatment
interval of 143 min in Medicare patients treated with direct
angioplasty and Canto et al. (13) reported median door-to-
balloon intervals ranging from 119 to 135 min. There is
persuasive experimental and observational evidence that
such delays are associated with worse survival. Berger et al.
(11) reported 30-day mortality of 1.0% for GUSTO IIb
patients with a randomization-to-balloon interval60 min,
3.7% for intervals of 61 to 75 min, 4.0% for intervals of 76
to 90 min and 6.4% for intervals 90 min. Using a
door-to-balloon interval of 60 min as a reference in an
analysis of data from the National Registry of Myocardial
Infarction (NRMI), Cannon et al. (14) found a multivariate
odds ratio for in-hospital mortality of 1.15 for door-to-
balloon intervals of 61 to 120 min, 1.41 for 121 to 150 min
and 1.62 for 151 to 180 min.
The study by de Boer et al. (6) raises several perplexing
practical issues, which are inseparable from broader ques-
tions about the current state of primary angioplasty in the
U.S. Primary angioplasty ideally depends on a systematic,
integrated approach to emergency care of AMI patients,
from initial treatment and triage by the emergency medical
system through timely emergency department response to
the simultaneous availability of an angiography suite, its staff
of technologists, nurses and assistants and a high-volume
interventional cardiologist. Like an eclipse, this perfect
alignment is a wonderful event when it occurs, but it occurs
rarely. Virtually no American hospital reserves a separate
angiography suite for emergencies, so scheduling delays are
common even during working hours; angioplasty staff are
not maintained on-site 24 h a day, so on nights and
weekends on-call staff must be summoned from home. Even
at large teaching institutions, American medicolegal con-
cerns preclude the apparent practice by de Boer et al. (6) of
using senior trainees to begin interventional procedures
immediately, without waiting for attending staff. As a result,
angioplasty for AMI remains a slow happenstance treat-
ment. In the Cannon et al. (14) analysis of data from the
NRMI, only 8% of patients had a door-to-balloon interval
of 60 min, the median in the study of de Boer et al. (6).
One question raised by the findings of de Boer et al. (6)
is whether, given the wretchedly delayed practice of primary
angioplasty in much of the world, their study can be fairly
extrapolated to other systems. The available data do not
permit an authoritative answer but they allow an educated
guess. Even assuming an angioplasty mortality of about 8%
in patients 75 years treated within 60 min and the
multivariate odds ratio of 1.6 reported by Cannon et al. (14)
for patients treated between 151 and 180 min after arrival,
there would still be substantial net benefit for angioplasty
compared to thrombolytic mortality of 18%. Randomized
trial data focusing specifically on elderly patients with
ST-elevation MI are urgently needed, but in its absence the
preponderance of the evidence would seem to favor primary
angioplasty over thrombolysis for patients 75 years at
hospitals with skilled acute angioplasty capability, even if
angioplasty involves summoning staff from home. The same
cannot be said for younger ST-elevation patients without
thrombolytic contraindications, for whom prolonged delay
for primary angioplasty is commonplace and unjustifiable.
Only about 40% of patients 75 years with ST-elevation
MI are treated at high volume hospitals with on-site
angioplasty capability (15). Thus, the second question raised
by the findings of de Boer et al. (6) is whether elderly
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patients who present to hospitals without angioplasty capa-
bility should be treated with intravenous thrombolytics or
with emergent transfer to a tertiary center, in conjunction
with a temporizing cocktail of aspirin, heparin, clopidogrel
and a glycoprotein IIb/IIIa inhibitor. Since the door-to-
balloon time for interhospital transfer often exceeds 3 h, this
question compares the much-diminished benefit of late
mechanical reperfusion (together with risk from ambulance
transfer) with the benefit or hazard of thrombolytic therapy
in patients 75 years, which is unknown (16).
Until randomized trial data are available comparing
thrombolytic therapy with delayed percutaneous interven-
tion in patients 75 years old, a nuanced, commonsense
approach seems reasonable. In urban areas where very rapid
transfer for immediate angioplasty is feasible, emergency
transfer can avoid the risks of thrombolysis. For other
hospitals, despite misgivings about the safety and effective-
ness of thrombolytic therapy in the elderly, randomized trial
evidence probably should govern treatment for patients who
present with widespread ST elevation, anterior MI or left
bundle branch block within perhaps 4 h of the onset of
sustained symptoms and without cardiogenic shock. For
elderly patients who present later, in whom the potential
benefit of thrombolytic therapy is dramatically diminished
and the risk is unchanged, and for those who have good left
ventricular function and small, well tolerated inferior or
lateral infarctions, emergency transfer for mechanical reper-
fusion may be more appropriate. Patients with cardiogenic
shock have shown no benefit from thrombolytic therapy
(17) and should be immediately transferred for mechanical
reperfusion.
As a practical matter, timely primary angioplasty for
patients 75 years does not occur in isolation, without
equally prompt treatment for younger patients. Analyses of
1994 to 1998 data from the NRMI (13) suggest that
roughly one-third of U.S. patients who receive reperfusion
therapy at hospitals with angioplasty capability undergo
primary angioplasty, a proportion that can only have in-
creased in the intervening years. Less than one-third of
these patients have a door-to-balloon interval of 90 min,
the standard of current American College of Cardiology/
American Heart Association guidelines, which themselves
reflect an implicit compromise between the remarkable
benefit of times 60 min and estimates of political and
logistical feasibility. Nearly half of primary angioplasty
patients nationwide have an interval 120 min, an uncon-
scionable delay in patients otherwise eligible for thrombo-
lytics. Both randomized and observational data increasingly
suggest that primary angioplasty involves a Faustian bar-
gain, providing a substantial mortality advantage compared
to thromboytic treatment for patients with short door-to-
balloon times and a survival disadvantage for patients with
delayed angioplasty, such as those who present at night and
on weekends. This disparity is the most likely reason for the
meager angioplasty benefit found in GUSTO IIb (8) com-
pared to smaller antecedent trials. The axiom that “time is
muscle” applies equally to thrombolytic and mechanical
reperfusion.
Most cardiologists, if they personally had an acute ante-
rior MI in an urban area, would want to be taken by
ambulance directly to a high volume hospital with an empty
table in the angiography suite, an experienced staff on-site,
a high volume interventionalist in attendance and a median
door-to-balloon time of 60 min. Although such an
integrated emergency system does not now exist, it might
halve the 30-day mortality from MI, as the study by de Boer
et al. (6) suggests. The aggregate data supporting such a
system vastly exceed the evidence that was used to develop
policy for regional trauma centers decades ago: about 60% of
MI patients are brought to the emergency department by
ambulance and such patients are a very high risk group, with
nearly three times the mortality of patients who arrive via
other transportation (18). Studies too numerous to fully cite
have shown better outcomes at high volume hospitals
(13,15), by high volume interventionalists (19,20) and with
short door-to-balloon times (11,14). In most urban and
suburban areas, hospitals are clustered so closely that trans-
port delays would be trivial (15), although the safety of
longer transport has not been tested. Yet nothing has been
done and very little has been said.
The unspoken reason for this remarkable inertia is eco-
nomic self-interest, together with a dearth of policy leader-
ship and of large clinical trials. Emergency medical system
administrators have demonstrated little interest in teleme-
tered 12-lead electrocardiograms, field triage criteria and
increased helicopter transportation or extended ambulance
run times to tertiary hospitals. Community hospital admin-
istrators, emergency department directors and cardiologists
are unlikely advocates for field triage directly to tertiary
facilities, which might reduce local occupancy and proce-
dural revenue. Administrators at tertiary hospitals, already
straining to staff angiography suites during regular hours,
cannot afford empty emergency angiography suites and
on-site staff 24 h a day. And the pharmaceutical industry,
the sponsor of nearly all large-scale clinical research in AMI,
would not benefit from integrated health care delivery. The
status quo benefits everyone but the patient.
The result has been an unhappy impasse. There has been
a movement to perform primary angioplasty at hospitals
without bypass surgery, thus providing economic incentives
to community hospitals and physicians while perpetuating
the belated practice of primary angioplasty that already
occurs at many tertiary hospitals. The economies of scale at
large centers are unarguable: no community hospital can
afford to maintain a standby angiography suite for emer-
gency cases or on-site 24-h staffing, prerequisites for timely
primary angioplasty. Common sense and observational ev-
idence also suggest that effective primary angioplasty de-
pends not only on the experience of the interventional
cardiologist but also on the training, expertise and system-
atic integration of the entire health care team, including the
emergency medical system, the emergency department, the
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catheterization laboratory and the coronary care unit, which
are impossible to maintain without volume and specializa-
tion.
The ideal solution, pioneered decades ago by trauma
surgeons and used for coronary care in some European
cities, probably is a system that combines field triage, direct
transportation of specified patients to designated cardiac
centers, 24-h on-site staffing by an interventional team and
guaranteed return to local practitioners for long-term
follow-up. Building such a system within acute care cardi-
ology—a largely fee-for-service specialty that has been
notably refractory to regulation and integration—is a for-
midable task. Clinical research in AMI has long focused on
small incremental benefits from drugs and devices, while
neglecting the huge potential benefit of health system
integration and timely primary angioplasty.
The clinical trial agenda is simple. In light of the findings
of de Boer et al. (6), there is a desperate need for definitive,
community-based, multicenter trials comparing intravenous
thrombolytic treatment with primary percutaneous translu-
minal coronary angioplasty in elderly patients, both within
tertiary hospitals and after emergent transfer from commu-
nity to tertiary centers. The next priority involves a para-
digm shift from drugs and devices within the current
fragmented system of care to health system integration,
beginning with the emergency medical system. Since a
minority of chest pain patients actually have an AMI,
derivation and validation of field triage criteria to identify
high-risk patients are urgently needed, along with quanti-
tative assessment of any risks from longer transport time.
Such studies would lay the groundwork for a large, random-
ized, community-based trial comparing field triage of high-
risk AMI patients directly to 24-h angioplasty centers with
transportation to the nearest hospital for thrombolytic
treatment if indicated.
The potential benefit of an integrated system for AMI
patients may seem self-evident to some, but sound public
policy and political reality both require rigorous research.
Such studies are unlikely to occur without targeted requests
for proposals from the National Institutes of Health. Re-
search on integrated health care delivery systems for AMI
patients is long overdue.
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